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The aim of this study was to verify FeNO usefulness, as a marker of bronchial inﬂammation, in the assessment of therapeutic
management of childhood asthma. We performed a prospective 1-year randomized clinical trial evaluating two groups of 32
children with allergic asthma: “GINA group”, in which therapy was assessed only by GINA guidelines and “FeNO group”,
who followed a therapeutic program assessed also on FeNO measurements. Asthma Severity score (ASs), Asthma Exacerbation
Frequency (AEf), and Asthma Therapy score (ATs) were evaluated at the start of the study (T1), 6 months (T2), and 1 year
after (T3). ASs and AEf signiﬁcantly decreased only in the FeNO group at times T2 and T3 (p[T1-T2] = 0.0001, and p[T1-T3]
= 0.01; p[T1-T2] = 0.0001; and p[T1-T3] < 0.0001, resp.). After six months of follow-up, we found a signiﬁcant increase of
patients under inhaled corticosteroid and/or antileukotrienes in the GINA group compared to the FeNO group (P = .02). Our
data show that FeNO measurements, might be a very useful additional parameter for management of asthma, which is able to
avoid unnecessary inhaled corticosteroid and antileukotrienes therapies, however, mantaining a treatment suﬃcient to obtain a
meaningful improvement of asthma.
1.Introduction
Asthma is characterized by variable degrees of airway
obstruction,hyperresponsiveness,andchronicinﬂammation
[1]. Current guidelines emphasize that inhaled corticos-
teroids (ICSs) represent the main treatment for asthma
becausetheytargettheunderlying airwaysinﬂammation[2].
Actually decisions to start ICSs and/or long-acting β2-
adrenergic agonist (LABA) and/or antileukotrienes (a-LT),
or change the dose are mainly based on symptoms reported
by the child or parents [3]. Nevertheless symptoms are
nonspeciﬁc and not closely related to the presence and
severity of airways inﬂammation [4]. Lung function tests
show only marginal correlation with airways inﬂammation
[5].
Bronchial epithelium produces Nitric Oxide (NO) [6],
and its fraction in exhaled air (FeNO) is elevated in atopic
asthma and reﬂects eosinophilic airways inﬂammation [7].
Many studies have shown that allergological markers corre-
late with FeNO levels, and particularly elevated FeNO levels
have been found mainly in atopic than in nonatopic asthma
[8–10].
Therefore, measurement of FeNO represents a noninva-
sive marker that may be a useful guide for the adjustment
of ICSs treatment [11]. The hypothesis of this study was to
verify if FeNO measure is useful in terms of better asthma
management in children. The aim of our study was to
examine whether the inclusion of repeated FeNO measure-
ments into asthma monitoring leads to an improvement in
asthma outcome, with an exacerbation reduction, clinical
improvement, and therapy score reduction.
2.Subjects
This was a prospective randomized study. We recruited 64
Caucasian children (36 males and 28 females; aged between2 Journal of Allergy
Table 1: Clinical characteristics of the population.
Characteristics “FeNO group” “GINA group”
M/F 18/14 18/14
Age (years) 10.7 ± 2.4 11.3 ± 2.1
Weight (Kg) 45.7 47.5
Height (cm) 149 152
Remission Asthma 7 7
Intermittent Asthma 18 19
Persistent Asthma 7 6
Asthma Duration (years) 5.7 ± 2.61 5.75 ± 2.27
6 and 17 years) who had been referred to the Allergological
and Pneumological Unity of the Pediatric Department,
University of Chieti, Italy, between January 2005 and January
2006. All subjects had been admitted for allergic asthma and
the diagnosis was made by a pediatric respiratory physician
on the basis of clinical history of repeated episodes of
coughing, dyspnea, and wheezing, according to ATS-ERS
criteria [12].
Patients were randomly allocated to two groups
(Table 1):
(i) “FeNO group” → 32 children (18 boys and 14 girls;
mean age, 10.7 ± 2.4 years)
(ii) “GINA group” → 32 children (18 boys and 14 girls;
mean age, 11.3 ± 2.1 years).
The whole study population was assessed at baseline
(T1), after a period of six months (T2), and at the end of
1-year followup (T3) (Table 2).
At baseline and at 6 months, in the GINA group, therapy
was based on symptoms, short acting β2-agonist use, and
lung function, according to GINA guidelines [13], while in
the FeNO group, therapy was assessed according also to
FeNO measurements.
The study was approved by the Ethical Committee of the
University of Chieti. Written informed consent was obtained
from all parents and oral consent from all children.
3. Methods
Asthma Severity score (ASS), Asthma Exacerbation fre-
quency(AEF),AsthmaTherapyscore(ATS),andimmunoal-
lergological and functional data were evaluated at the start of
the study (T1), 6 months (T2), and 1 year later (T3).
Asthma was classiﬁed according to GINA guidelines to:
Intermittent Asthma, Mild Persistent, Moderate Persistent,
and Severe Persistent Asthma, considering the 6 months
before the beginning of the study [13].
3.1. Asthma Severity Score (ASS). It was assessed as
(i) Intermittent Asthma = Score 1,
(ii) Mild and Moderate Persistent Asthma = Score 2,
(iii) Severe Persistent Asthma = Score 3.
We also assessed an arbitrary implementation of asthma
classiﬁcation by GINA criteria, and performed the following
score for these two phenotypes of asthma:
(i) Remission Asthma = Score 0,
(ii) Exercise induced Asthma = Score 2.
3.2. Asthma Exacerbation Frequency (AEF). It was assessed
with an anamnestic questionnaire evaluating frequency of
asthma exacerbation (deﬁned as the number of episodes of
coughing, dyspnea, and wheezing, according to ATS-ERS
criteria [12], requiring short-acting β2-adrenergic agonist)
during the 6 months before the beginning of the study,
between T1 and T2 and between T2 and T3 evaluations.
3.3. Asthma Therapy Score (ATS). It was assessed with an
anamnestic questionnaire and an arbitrary score, as follows:
(i) Antihistamines, Ketotifen, Cromones = Score 1,
(ii) Speciﬁc Immuno Therapy (SIT), long-acting β2-
adrenergicagonist(LABA)orantileukotrienes(a-LT)
= Score 2,
(iii) ICSs = Score 3.
3.4. Allergic Sensitization. It was evaluated by Skin Prick
Test (SPT) and serum-speciﬁc IgE measurements for the
most common respiratory allergens: Dust Mite (Derma-
tophagoides Pteronyssinus, and Farinae), Grass, Parietaria,
Artemisia Vulgaris, Olive, Cypress, Lime, Stone, Elm, Plane,
Cat and Dog dander, Alternaria Alternata, and Aspergillus
Fumigatus(moulds).DeterminationofAllergen-SpeciﬁcIgE
was made by an Immunoenzymatic Allergo-sorbent Test
(Cap test Pharmacia) [14, 15].
3.5. Inﬂammatory Cells. Peripheral blood eosinophil counts
and serum eosinophil cationic protein (s-ECP) levels were
measured by immunoﬂuorescence.
3.6. Respiratory Function. E v a l u a t i o n sw e r em a d eb yF l o w /
Volume, curves, Static Lung Volume and Plethysmographic
Airway Resistances determination according to ATS/ERS
Guidelines [16, 17].
3.7. Respiratory Inﬂammation. All children of the FeNO
groupunderwentFeNOanalysis.FeNOwasdeterminedwith
an on-line method using a single breath exhalation and
a sensitive chemiluminescence assay (Ecomedics CLD 88),
according to ATS-ERS [18]. Patients made an inspiration
of eNO-free air via a mouthpiece immediately followed by
full exhalation at a constant rate (50mL/sec) for at least 5
seconds. The mean of three readings at the end of the expi-
ration (plateau phase) was taken as the representative value
for each measurements. 12ppb or more were considered
elevated values, according to ATS-ERS criteria [19].Journal of Allergy 3
Table 2: Study design.
T1 T2 (6 m) T3 (12 m)
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“GINA group”
“FeNO group”
Diary card Diary card
Clinical evaluation Clinical evaluation Clinical evaluation
Allerg. evaluation Allerg. Evaluation
Lung Function Tests Lung Function Tests Lung Function Tests
FeNO measurements FeNO measurements FeNO measurements
Score therapy Score therapy Score therapy
4.StatisticalAnalysis
All values were expressed as means and SD. We analysed
diﬀerences in variables (ASS, ATS, AEF, and respiratory
function test) obtained at diﬀerent times between the two
groups by unpaired T-test, and within each group with
paired T-test. Statistical signiﬁcance level was P< . 05.
The comparison of the diﬀerences in AEF and in ATS
between the two groups was calculated also using the Chi
square (χ2) Test.
The number of antiasthmatic drugs used in the two
groups was calculated at T1, T2, and T3.
In the “FeNO group”, level of 12ppb was the cut-oﬀ used
to guide the therapeutic management [at 6 months of the
follow-up study (T2)], according to the ERS-ATS Statement
of 2001 [19].
Values above 12ppb were considered as an indication to
increase the number of drugs, whereas values below 12ppb
lead to a reduction or to a maintenance in the amount of
drugs.
5. Results
The two groups were similar for age, sex, weight, and height
without signiﬁcant diﬀerences. All the children of both
groups were allergic to Dermatophagoides Pteronyssinus
(Df. pt). At the ﬁrst assessment, patients’ asthma character-
istics were similar between the two groups. Asthma Severity
score(ASS),AsthmaExacerbationsfrequency(AEF),Asthma
Therapy score (ATS), functional and immunoallergologi-
cal (circulating eosinophils, s-ECP, total and speciﬁc IgE)
parameters did not show any signiﬁcant diﬀerence between
the two groups at T1. ASS mean values signiﬁcantly decrease
in the FeNO group at T2 and T3 (from 1.09 ± 0.81 to
0.56±0.75 at T2, p[T1-T2] = 0.001,a n dt o0 .75±0.95 at T3,
p[T1-T3] =0 . 0 1 ,r e s p . ) ,w h i l en od i ﬀerence was detected in
theGINAgroupinthecorrespondingtimes(from1.09±0.77
to 0.93±0.61 at T2, p[T1-T2] = 0.1, and to 0.92 ± 0.82 at T3,
p[T1-T3] = 0.1) (Figure 1).
Similarly, AEF evaluation showed a signiﬁcant reduction
in the number of episodes in the FeNO group at T2 and
T3 (Mean values: from 1.96 ± 1.18 to 1.01 ± 0.96 at T2,
p[T1-T2] = 0.0003, and to 0.83 ± 0.98 at T3, p[T1-T3] =
0.0001)b u tn o ti nt h eG I N Ag r o u p( M e a nv a l u e s :f r o m
2.01 ± 1.17 to 1.78 ± 1.29 at T2, p[T1-T2] = 0.08; and
to 1.85 ± 1.34 at T3, p[T1-T3] = 0.14) (Figure 2). Using
the Chi-square (χ2) Test we found a signiﬁcant decrease of
the number of patients with asthma exacerbation only in
the FeNO group at T2 (P = .0006) and at T3 (P<. 05)
(Figure 3).
In addition in the FeNO group, there was no increase in
antiasthmatic therapy (Mean values of ATS were similar in
the 3 evaluations), (1.5 ± 0.7 in T1; 1.43 ± 0.7 in T2, and
1.53 ± 0.6 in T3) while in the GINA group, the treatment
was signiﬁcantly step up (Mean values: from 1.03 ± 0.9
to 1.62 ± 0.6 at T2, p[T1-T2] < 0.05,a n dt o1 . 4± 0.7
at T3, p[T2-T3] < 0.05; p[T1-T3] < 0.05), as shown in
Figure 4.
Using the Chi square (χ2) Test, we found a signiﬁcative
diﬀerence in the number of patients who did not use ICS
and/or a-LT after 6 months between the FeNO group (5/32
= 15%) in comparison to the GINA group (2/32 = 6%) [T2:
P = .02]. No signiﬁcant diﬀerence was found between the
two groups at the end of the study; nevertheless, a careful
observation relative to the therapy revealed a light diﬀerence
among the two groups about the anti-inﬂammatory drugs
use. In fact, the FeNO group keeps the same therapy, while
the GINA group showed an increased use of ICSs and a-LT
(Figure 5).
T h ee v a l u a t i o no fF e N Ol e v e l si nF e N Og r o u pd e m o n -
stratedasigniﬁcantreductionafter6monthsoftherapy,with
a return at the levels of the beginning at the end of the study
(Mean values of FeNO: from 13.78 ± 12.31 to 9.51 ± 11.04 at
T2, p[T1-T2] = 0.0006, and to 13.53 ± 10.74 at T3, p[T2-T3]
= 0.005;p [ T 1 - T 3 ]= 0.44).
No signiﬁcant diﬀerence was found between the two
groups in terms of respiratory function test and of imunoal-
lergological parameters.4 Journal of Allergy
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Figure 1: Asthma Severity score (ASS) in FeNO and GINA groups at the ﬁrst evaluation (T1) after 6 months (T2) and after 1 year of therapy
(T3). Mean Values ± SD.
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Figure 2: Asthma Exacerbation frequency (AEF) in the FeNO and GINA groups at the ﬁrst evaluation (T1) after 6 months (T2) and after 1
year of therapy (T3). Mean Number of episodes ± SD.Journal of Allergy 5
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Figure 3: Number of patients with and without asthma exacer-
bation in FeNO and GINA groups at ﬁrst evaluation (T1), after 6
months (T2) and after 1 year of therapy (T3).
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Figure 4: Antiinﬂammatory drugs level in both group at each
evaluation. Mean Values ± SD.
6. Discussion
This study shows that FeNO measurements are useful in
childhood asthma management because FeNO reductions
are related to improvement in clinical score with a reduction
of asthma exacerbation. In our study, FeNO reductions were
not related to any improvement of respiratory function but
allow to keep the same therapeutic regimen in the “FeNO
group”, while in the “GINA group”, we had a signiﬁcant
increase of number of patients who use antiinﬂammatory
drugs (mainly ICS) without any evidence of increase in
bronchial inﬂammation.
Previous studies have shown a signiﬁcant correlation
between FeNO and respiratory symptoms, bronchial hyper-
responsiveness (BHR), and blood eosinophilia but not with
spirometric indices of lung function [20, 21]. These ﬁndings
are in agreement with data reported by Silvestri and cowork-
ers [22] who demonstrated that airways inﬂammation may
not be strictly related to a reduction in lung volumes or to
the degree of airﬂow limitation.
Recent studies revealed that FeNO is a potentially useful
measure to evaluate the role of airways inﬂammation in
asthma, as it represents the forerunner of an important event
in asthma: the remodelling of bronchial airway [23].
Current guidelines recommended to adjust the dose of
these drugs on the basis of symptoms and LFTs results
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Figure 5: Antiinﬂammatory drugs trend: variation of the number
of patients that use antiinﬂammatory drugs.
[13]. However, recent studies demonstrated that the use
of alternative criteria, like BHR, FeNO levels, and sputum
eosinophils, leads to an improvement in asthma treatment
outcomes [24].
The ICSs therapy produces a rapid reduction (dose-
dependent) of FeNO levels in asthmatic subjects. Some stud-
ies demonstrated that the reduction of FeNO levels occurs at
the same time of the reduction of sputum eosinophils [25].
The elevated sensitivity of FeNO levels to ICSs therapies
shows that it can be used as a factor of prediction for anti-
inﬂammatory therapy, and could be an indicative marker
to detect patients that do not have a good compliance to
therapy. Also the anti-LT drugs association could improve
FeNO levels, while LABA does not reduce it [26, 27].
Therefore, exhaled nitric oxide may be a valuable parameter
to monitor adherence to steroids, although it is less suitable
to describe physiologically relevant impairments of lung
function [28].
In our study, we found a reduction of clinical symptoms
and asthma exacerbations in the FeNO group. Furthermore,
we found also an improvement of respiratory function and
therapeutic score. We demonstrated that measurement of
airways inﬂammation is of practical value in management
of asthmatic children because it allows to monitor patients
from a “ﬂogistic” point of view. It leads to an improvement
of clinical outcome and to a reduction in number of
exacerbations. Furthermore, diﬀerently from other studies,
in our study FeNO measurement did not permit to reduce
the use of drugs but allows us to not increase the amount
of drugs as it has been done in GINA group. In particular, we
underliedamildincreaseoftherapeuticscoreinFeNOgroup
due to an increase of drugs dose to reach a good clinical
outcome. Only a few longitudinal studies have examined the
possible clinical relevance of FeNO in asthma management.
Roberts and coworkers [29] have demonstrated that FeNO
relates to previous allergen exposure and asthma control.
Pijnenburg et al. [30] demonstrated that FeNO is helpful
in predicting asthma relapse in children who discontinue
ICSs because of clinical remission. Similarly, the study of
Zacharasiewicz et al. [2] performed on 40 children with6 Journal of Allergy
stable asthma eligible for inhaled steroid reduction has
showed that elevated values of sputum eosinophil and
FeNO were a signiﬁcant predictor for failed ICSs reduction
in children with apparently well-controlled asthma. These
ﬁndings suggest that monitoring airway inﬂammation may
be useful in optimizing treatment in childhood asthma. In
a recent single-blind controlled trial in adult with asthma,
Smith and colleagues [31] showed that using FeNO for
adjustments of ICSs leads to similar asthma control with less
ICS in the FeNO-treated group compared with the group
treated on conventional parameters; the FeNO levels can
oﬀer a method to adjust the doses of ICSs. Indeed, use of
FeNOmeasurementsmayalsohelptominimizethepotential
long-term side eﬀects related to ICSs, which are more likely
when higher doses are used. Also in the clinical trial of
Pijnenburg et al. [3], performed on 85 children with asthma,
1 year of steroids titration FeNO did not result in higher
steroid doses and did improve airway hyperresponsiveness
and inﬂammation compared with titrating on symptoms
only.
7. Conclusion
Our results have shown that the use of noninvasive methods
to monitor airway inﬂammation, as FeNO measure, can
help to guide treatment in childhood asthma management.
We demonstrate that repeated FeNO measurement can
help to optimize asthma therapy with improvement in
asthma severity and exacerbation. These ﬁndings conﬁrm
the important role of FeNO in the routine assessment of
children with asthma in clinical practice, especially when
decisions about treatment need to be made. Overall, this
approach oﬀers a logical complementary item to the use of
clinicalandfunctionaldataleadingtoamoreﬁttedtreatment
in childhood asthma management to reach a good clinical
outcome and a reduction of exacerbations. Our study shows
that FeNO measurement does not allow only a reduction of
drugs use but also a better personal ﬁtted therapy suﬃcient
to obtain good clinical control.
Further prospective studies on lager populations of
children are required to conﬁrm these conclusions.
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